AI
PNT

Atom Investors’s POINT Biopharma Global Inc. Common Stock PNT Stock Holding History

Atom Investors’s Portfolio PNT Stock Details PNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-31,821
Closed -$231K – 392
2023
Q1 		$231K Sell
31,821
-41,160
-56% -$305K 0.13% 184
2022
Q4 		$532K Buy
72,981
+9,812
+16% +$72.8K 0.27% 83
2022
Q3 		$488K Buy
63,169
+52,376
+485% +$445K 0.17% 152
2022
Q2 		$74K Sell
10,793
-49,310
-82% -$377K 0.03% 227
2022
Q1 		$479K Buy
60,103
+43,007
+252% +$273K 0.22% 104
2021
Q4 		$96K Buy
+17,096
New +$128K 0.02% 246

Other funds holding PNT

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Atom Investors's PNT Position: Q2 2023 in Review

Atom Investors sold out of POINT Biopharma Global Inc. Common Stock (PNT) in Q2 2023, closing a stake of 31,821 shares — an estimated $231K sold.

Atom Investors first reported a position in PNT in Q4 2021 and held it in 6 quarters. The position peaked at $532K in Q4 2022. 130 funds tracked by Wall St. Rank hold PNT as of Q2 2023.

  • Atom Investors reported no remaining POINT Biopharma Global Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Atom Investors sold 31,821 POINT Biopharma Global Inc. Common Stock shares in Q2 2023, an estimated $231K.
  • Atom Investors first reported a position in POINT Biopharma Global Inc. Common Stock in Q4 2021 and held it in 6 quarters.
  • Atom Investors's POINT Biopharma Global Inc. Common Stock position peaked at $532K in Q4 2022.
  • 130 funds tracked by Wall St. Rank held POINT Biopharma Global Inc. Common Stock as of Q2 2023.

Based on Atom Investors's 13F filing for Q2 2023, filed 14 Aug 2023.